Clinical Trial Update: A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies [Phase 3]

View source ↗

Summary

Phase 3 trial comparing lisocabtagene maraleucel vs investigator's choice in adult relapsed/refractory CLL/SLL has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Lisocabtagene maraleucel (lisocabtagene maraleucel)

Snippet

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Conditions: Leukemia, Lymphocytic, Chronic, B-Cell | Phase 3 | Status: WITHDRAWN